P-CD19CD20-ALLO1 Cells

BIOLOGICAL2 trials

Sponsors

Genentech, Inc.

Conditions

Multiple SclerosisSystemic Lupus Erythematosus

Phase 1

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

WithdrawnNCT06984341

Genentech, Inc.Systemic Lupus Erythematosus

Start: 2026-06-30End: 2033-11-01Updated: 2026-08-05

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Active, not recruitingNCT07008378

Genentech, Inc.Multiple Sclerosis

Start: 2025-10-15End: 2032-08-31Target: 60Updated: 2026-07-15